CompletedNot Applicable

The Predictive Role of Preoperative Pentraxin-3 (PTX3) in Metabolic and Inflammatory Outcomes After Roux-en-Y Gastric Bypass

23 participantsStarted 2015-01-01

Plain-language summary

This study evaluated the prognostic value of preoperative pentraxin-3 (PTX3) levels in predicting weight loss, inflammatory resolution (CRP, IL-6), and metabolic improvements (HOMA-IR) following Roux-en-Y gastric bypass in patients with obesity.

Who can participate

Age range18 Days – 65 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age: 18-65 years * Body mass index (BMI) ≥40 kg/m², or BMI ≥35 kg/m² with obesity-related comorbidity * Eligible for primary Roux-en-Y gastric bypass * Able to provide written informed consent Exclusion Criteria: * Previous bariatric surgery * Severe hepatic, renal, or cardiac failure * Active infection or inflammatory disease * Malignancy

What they're measuring

Change in HOMA-IR from baseline to 6 months

Timeframe: Baseline, 3 months, 6 months

Trial details

NCT IDNCT07241741

SponsorIstanbul University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2015-07-01

View on ClinicalTrials.gov More Obesity trials